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Abstract
Introduction: We recently found that platelet cytochrome c oxidase (COX) activities and quantities in 6-month-
survival septic patients are significantly higher than those of patients who died before 6 months. Other studies
suggested that the mitochondrial DNA (mtDNA) genotype could play a major role in sepsis survival. Given that
COX catalytic subunits are encoded by mtDNA, the objective of the present study was to explore whether mtDNA
population genetic variation could affect COX activity and quantity and favors sepsis survival.
Methods: A prospective, multicenter, observational study was carried out in six Spanish ICUs. We included 96
patients with severe sepsis. We determined the mtDNA haplogroup, the COX specific activity/citrate synthase
specific activity (COXa/CSa) ratio and the COX quantity/citrate synthase specific activity (COXq/CSa) ratio in
circulating platelets at the time of diagnosis, day 4 and day 8. We used survival at 1 and 6 months as endpoints.
Results: Patients with the JT mtDNA haplogroup (n = 15) showed higher COXq/CSa ratio at day 4 (P = 0.04) and
day 8 (P = 0.02) than those with other haplogroups (n = 81). Logistic regression analysis showed that the JT
mtDNA haplogroup (odds ratio = 0.18; 95% confidence interval = 0.04 to 0.94; P = 0.04) and COXq/CSa ratio (odds
ratio = 0.53; 95% confidence interval = 0.30 to 0.93; P = 0.03) were associated with 1-month survival after
controlling for age and lactic acid levels.
Conclusions: The novel findings of our study are that 1-month surviving septic patients showed higher COXq/CSa
ratio than nonsurviving individuals, that patients from the JT mtDNA haplogroup showed a higher COXq/CSa ratio
and that JT patients had a higher 1-month survival than patients from other mtDNA haplogroups.
Introduction
Sepsis is a common, expensive, and frequently fatal condi-
tion [1,2]. The physiopathologic mechanisms of sepsis are
not well known, but it has been proposed that organ dys-
function during sepsis is associated with tissue hypoxia
due to cellular inability to use oxygen because of mito-
chondrial dysfunction [3]. Respiratory complex IV or cyto-
chrome c oxidase (COX) is responsible for most cellular
oxygen consumption. We have recently found that platelet
COX activities and quantities in 6-month-survival patients
are significantly higher than those of patients who do not
survive 6 months [4]. COX contains 13 polypeptides and
three of them are encoded by mitochondrial DNA
(mtDNA) [5]. We have also found that transmitochondrial
cell lines (cybrids) harboring different mtDNA genetic
backgrounds (haplogroups) showed differences in COX
activities and quantities. In particular, cybrids from hap-
logroup H had higher COX activities and quantities than
those from haplogroup Uk [6]. Because cybrids are pro-
duced by the fusion of cells without mtDNA (rho0 cells) to
platelets with mitochondria and mtDNA but lacking a
nucleus, different cybrid cell lines contain the same
nuclear background and different mitochondrial genotype
- therefore, phenotypic differences between them must be
due to their particular mtDNA genome. These observa-
tions suggest that the mtDNA genotype could play a
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major role in determining COX quantity and activity and,
finally, affecting sepsis survival.
Supporting the previous hypothesis, the mtDNA
macrolineage R was found in the Chinese Han popula-
tion to be a strong independent predictor of outcome in
severe sepsis, conferring an increased chance of long-
term survival [7]. In China, macrolineage R mainly
includes haplogroups B and F that represent around
35% of the population. In Europe, this macrolineage
includes different haplogroups from those of Asian R.
These haplogroups are HV, JT and U (Figure 1),
together representing around 90% of the European
population [8]. Haplogroup HV contains haplogroup H
and is the most prevalent European haplogroup. In Eng-
land, haplogroup H has also been found to be a strong
independent predictor of outcome during severe sepsis,
conferring increased chance of survival at 180 days [9].
Chinese and European populations, however, are very
different from a mtDNA point of view [10]. Moreover,
despite the frequencies of Western Europe mtDNA hap-
logroups being very similar, the distribution of mtDNA
subhaplogroups is probably not so similar [11]. More
studies are therefore required to delimitate mtDNA
polymorphisms related to sepsis survival. Moreover, a
direct intermediate phenotype - linking the relationship
between mtDNA haplogroups, mitochondrial function
and sepsis survival - has not been analyzed in previous
studies. The objective of the present study was thus to
explore whether population genetic variation in mtDNA
could affect COX activity and quantity, and could mod-
ify the risk of sepsis survival.
Materials and methods
Design and subjects
An exploratory, prospective, multicenter, observational
study was carried out in six Spanish ICUs. Institutional
review boards from these hospitals approved the study.
Written informed consent was obtained from patients
or family members. We determined the mtDNA hap-
logroup in 96 patients with severe sepsis that have been
previously published [4].
The diagnosis of sepsis and severe sepsis was estab-
lished according to the criteria laid down by the Inter-
national Sepsis Definitions Conference [12]. Severe
sepsis was defined as sepsis complicated by organ dys-
function. Sepsis was defined as a documented or sus-
pected infection and some of the following parameters:
general parameters - fever (core temperature > 38.3°C),
hypothermia (core temperature < 36.0°C), tachycardia
(heart rate > 90 beats/minute), tachypnea (respiratory
rate > 30 breaths/minute), altered mental status, signifi-
cant edema or positive fluid balance (higher than 20 ml/
kg over 24 hours), or hyperglycemia (plasma glucose >
110 mg/dl) in the absence of diabetes; inflammatory
parameters - leukocytosis (white blood cell count >
12,000/mm3), leukopenia (white blood cell count <
4,000/mm3), normal white blood cell count with a per-
centage of immature forms higher than 10%, plasma C
reactive protein > 2 standard deviations above the nor-
mal value, or plasma procalcitonin > 2 standard devia-
tions above the normal value; hemodynamic parameters
- arterial hypotension (systolic blood pressure < 90
mmHg, mean arterial blood pressure < 70 mmHg, or
decrease of systolic blood pressure from the baseline >
40 mmHg), mixed venous oxygen saturation > 70%, or
cardiac index > 3.5 l/minute/m2; organ dysfunction -
arterial hypoxemia (PaO2/FIO2 ratio < 300), acute oli-
guria (urine output < 0.5 ml/kg/hour for at least 2
hours), increased creatinine ≥ 0.5 mg/dl, thrombocyto-
penia (platelet count < 100,000/mm3), or hyperbilirubi-
nemia (total bilirubin > 4 mg/dl); and tissue perfusion
parameters - hyperlactatemia (> 3 mmol/l), decreased
Figure 1 Human mitochondrial DNA haplogroups.
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capillary refill or mottling. Exclusion criteria were: age <
18 years; pregnancy; lactation; infection by HIV; white
blood cell count < 1,000/mm3; solid or hematological
tumor; or immunosuppressive, steroid or radiation
therapy.
The following variables were recorded for each
patient: gender, age, diabetes mellitus, chronic obstruc-
tive pulmonary disease, ischemic heart disease, ischemic
stroke, site of infection, microorganism responsible,
bloodstream infection, empiric antimicrobial therapy,
mean blood pressure, septic shock, need for and dose of
norepinephrine, need for and dose of dobutamine,
PaO2/FIO2 ratio, creatinine, bilirubin, leukocytes, lactic
acid, platelets, International Normalized Ratio, activated
partial thromboplastin time, Acute Physiology and
Chronic Health Evaluation II score [13] and Sepsis-
related Organ Failure Assessment score [14]. We used
survival at 1 and 6 months as endpoints. Empiric anti-
microbial therapy was considered adequate if the micro-
organism responsible for sepsis was susceptible at least
to one antimicrobial agent used.
Haplogroup classification
Blood samples were collected at the time of diagnosis of
severe sepsis. DNA was extracted following standard pro-
tocols and the mtDNA haplogroup was determined by
real-time PCR. Three SNPs defining haplogroups JT
(4216), H (7028) and U (12308) were genotyped in all of
the samples. Fourteen other mtDNA SNPs (1811, 3010,
4336, 4580, 4769, 9477, 10873, 13708, 14766, 14793,
14798, 15218, 15257 and 15693) were established using a
phylogenetic approach to confirm particular haplogroups
(Figure 1) [15]. The real-time PCR was performed with
TaqMan reagents (Applied Biosystems, Austin, TX,
USA). For each SNP, reagents included two primers
around the SNP and two probes: a fluorophore VIC-
labeled probe specific for one allele and another fluoro-
phore FAM-labeled probe specific for the other allele.
DNA was amplified in a final volume of 25 μl, using 12.5
μl TaqMan Gene Expression Master Mix, 0.9 μM each
primer, 0.2 μM each probe and 10 ng total DNA. The
amplification was performed using universal conditions.
Biochemical determination of COX activity and quantity
in patients’ platelets
Blood samples were collected at the time of diagnosis of
severe sepsis, day 4 and day 8. Patients’ platelets were
obtained according to previously described protocols
[16], and protein levels [17] and citrate synthase (CS)
specific activity [18] were assayed. We also determined
platelets’ COX specific activity and quantity by a spec-
trophotometric assay using Mitoprofile Human Complex
IV Activity and Quantity from Mitosciences (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s
instructions. This kit immunocaptures complex IV, and
the activity is determined by following the oxidation of
reduced cytochrome c as an absorbance decrease at 550
nm. Subsequently, in the same well, the quantity of
enzyme is measured by adding a complex IV specific
antibody conjugated with alkaline phosphatase.
COX activities and quantities are expressed as milliop-
tical density per minute per milligram of protein. The
specific activity of CS was also expressed as millioptical
density per minute per milligram of protein. To correct
for potential differences in the mitochondria number of
platelets, we normalized COX specific activities and
quantities by CS specific activity (COXact/CSact and
COXqua/CSact).
Statistical analysis
Continuous variables are reported as medians and inter-
quartile ranges. We used a Kruskal-Wallis analysis of
variance to compare the four haplogroups before pair
comparisons with the Wilcoxon-Mann-Whitney test of
continuous variables. Categorical variables are reported
as frequencies and percentages, and were compared by
chi-square test.
As the COX quantity/CS specific activity and COX
specific activity/CS specific activity ratios were not nor-
mally distributed, we created two logarithmically trans-












Logistic regression analyses were used to test the asso-
ciation of JT mtDNA haplogroups and COXq/CSa ratio
with survival at 1 and 6 months, controlling for age and
lactic acid levels. Odds ratios and their 95% confidence
intervals were calculated as measures of the association.
Analysis of survival at 1 and 6 months with the
Kaplan-Meier method curve and comparisons by log-
rank test were carried out using JT haplogroup versus
non-JT mtDNA haplogroup as the independent variable
and survival at 1 and 6 months as the dependent vari-
able. P < 0.05 was considered statistically significant.
When Bonferroni correction was used to correct multi-
ple comparisons in repeated measures between the JT
and other haplogroups [20], P < 0.008 was considered
statistically significant (p = 0.05/6 = 0.008).
Statistical analyses were performed using SPSS 17.0
(SPSS Inc., Chicago, IL, USA) and Med Calc (Maria-
kerke, Belgium).
Results
We found significant differences between mtDNA hap-
logroups in COXq/CSa ratios at day 4 (P = 0.04) and
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day 8 (P = 0.02) (Table 1). Specifically, patients from the
JT mtDNA haplogroup showed a higher COXq/CSa
ratio at day 4 than those from the HV (P = 0.005) and
U (P = 0.02) mtDNA haplogroups; and a higher ratio at
day 8 than those of the HV (P = 0.007) and U (P =
0.004) mtDNA haplogroups.
Table 2 shows patients’ demographic and clinical
characteristics according to mtDNA haplogroups.
Despite the percentage of 1-month and 6-month survi-
val being higher in JT individuals than in those from
other mtDNA haplogroups, we did not find significant
differences. Interestingly, there were significant differ-
ences in lactic acid levels between these major European
haplogroups. The JT haplogroup thus had the higher
age and higher lactic acid levels, variables which have
been associated with sepsis survival in different studies
[1,4,21-24]. A random accumulation of older individuals
with higher lactic acid levels from the JT haplogroup in
our sample could therefore possibly counteract the ben-
eficial effects of a higher COXq/CSa ratio on survival.
Therefore, as we found significant differences between
mtDNA haplogroups in COXq/CSa ratios and differ-
ences, although not statistically significant, in the survi-
val rate between mtDNA haplogroups in favor of JT
mtDNA haplogroup, we included a subanalysis compar-
ing the JT mtDNA haplogroup versus other
haplogroups.
In the analysis of the JT haplotype versus other hap-
logroups, we found higher COXa/CSa and COXq/CSa
ratios at days 1, 4 and 8 in individuals from the JT hap-
logroup (Table 3). After the Bonferroni correction for
multiple analyses, however, only the COXq/CSa ratio at
days 4 and 8 was significantly higher in JT individuals.
We found a higher, not statistically significant, survival
rate in patients from the JT mtDNA haplogroup than in
those from other haplogroups at 6 months (73.3% vs.
53.1%; P = 0.17) and at 1 month (86.7% vs. 61.7%; P =
0.08) (Table 4).
Logistic regression analyses showed that the JT hap-
logroup was associated with higher survival at 1 month
(odds ratio = 0.18; 95% confidence interval = 0.04 to
0.94; P = 0.04) after controlling for age and lactic acid
levels (Table 5). Logistic regression analyses also showed
that the COXq/CSa ratio was associated with higher
survival at 1 month (odds ratio = 0.53; 95% confidence
interval = 0.30 to 0.93; P = 0.03) and at 6 months (odds
ratio = 0.56; 95% confidence interval = 0.34 to 0.93; P =
0.03) after controlling for age and lactic acid levels
(Table 5).
We have not been able to demonstrate in Kaplan-
Meier analyses that the JT haplogroup was associated
with higher survival at 1 month (log-rank test = 2.84; P
= 0.09) and 6 months (log-rank test = 2.01; P = 0.16)
(Figure 2).
Discussion
We had previously found that 6-month survival in sepsis
patients was significantly associated with platelet COX
quantity [4]. However, 1-month survival is a more fre-
quently used parameter in critically ill patients; and we
have found that this parameter is also significantly asso-
ciated with platelet COX quantity. We had previously
observed that COX levels can be determined by mtDNA
genetic background [6], and other investigators showed
that mtDNA haplogroups modified 6-month survival
[9]. Here we show that the mtDNA haplogroup deter-
mines the platelet COX quantity in sepsis patients and
that those patients from the JT mtDNA haplogroup had
higher survival rate than those from other mtDNA
haplogroups.
The JT mtDNA haplogroup is defined by poly-
morphisms in nucleotide positions m.4216T > C/MT-
ND1, m.11251A > G/MT-ND4, m.15452C > A/MT-
CYB and m.16126T > C/MT-DLOOP. The last poly-
morphism is located in the control region, out of any
important sequence for the regulation of mtDNA
Table 1 COXa/CSa and COXq/CSa ratios according to mitochondrial DNA haplogroup
Haplogroup
HV U JT No R P value
Time of diagnosis (n = 44) (n = 24) (n = 15) (n = 13)
COXa/CSa ratio 2.83 (2.34 to 3.17) 2.90 (2.24 to 3.17) 3.25 (2.63 to 3.56) 2.81 (2.39 to 3.09) 0.28
COXq/CSa ratio 1.71 (1.26 to 2.90) 1.89 (1.18 to 2.85) 2.72 (1.57 to 3.38) 2.23 (1.31 to 3.31) 0.41
Day 4 (n = 34) (n = 18) (n = 10) (n = 10)
COXa/CSa ratio 2.73 (2.41 to 3.30) 2.93 (2.45 to 3.16) 3.24 (3.04 to 3.33) 2.85 (2.39 to 3.04) 0.10
COXq/CSa ratio 1.53 (1.26 to 2.99) 2.14 (1.34 to 3.18) 3.10 (2.52 to 3.45) 2.51 (1.23 to 3.34) 0.04
Day 8 (n = 32) (n = 14) (n = 10) (n = 9)
COXa/CSa ratio 2.68 (2.22 to 3.23) 2.72 (2.39 to 3.23) 3.07 (2.83 to 3.15) 3.04 (2.32 to 3.41) 0.41
COXq/CSa ratio 1.59 (1.19 to 3.06) 1.63 (1.21 to 2.79) 3.39 (2.61 to 3.52) 2.91 (1.24 to 3.44) 0.02
Data presented as median (interquartile range). COXa/CSa, cytochrome c oxidase specific activity/citrate synthase specific activity; COXq/CSa, cytochrome c
oxidase quantity/citrate synthase specific activity.
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Table 2 Patients’ demographic and clinical characteristics according to mitochondrial DNA haplogroup
Haplogroup
HV (n = 44) U (n = 24) JT (n = 15) No R (n = 13) P value
Gender, male 28 (63.6) 17 (70.8) 8 (53.3) 7 (53.8) 0.64
Age (years) 57 (46 to 65) 62 (52 to 74) 64 (54 to 81) 50 (39 to 66) 0.06
Diabetes mellitus 21 (47.7) 9 (37.5) 4 (26.7) 2 (15.4) 0.14
COPD 5 (11.4) 3 (12.5) 1 (6.7) 1 (7.7) 0.92
Ischemic heart disease 3 (6.8) 2 (8.3) 1 (6.7) 1 (7.7) 0.99
Ischemic stroke 2 (4.5) 1 (4.2) 0 0 0.73
Site of infection 0.97
Respiratory 31 (70.5) 16 (66.7) 8 (53.3) 7 (53.8)
Abdominal 8 (18.2) 4 (16.7) 5 (33.3) 4 (30.8)
Urinary 1 (2.3) 1 (4.2) 1 (6.7) 1 (7.7)
Skin 2 (4.5) 2 (8.3) 1 (6.7) 1 (7.7)
Endocarditis 1 (2.3) 1 (4.2) 0 0
Others 1 (2.3) 0 0 0
Microorganism responsible
Unknown 23 (52.3) 13 (54.2) 6 (40.0) 7 (53.8) 0.83
Gram-positive 11 (25.0) 6 (25.0) 5 (33.3) 2 (15.4) 0.75
Gram-negative 9 (20.5) 5 (20.8) 4 (26.7) 4 (30.8) 0.85
Fungi 3 (6.8) 1 (4.2) 0 0 0.62
Anaerobe 1 (0.8) 0 0 0 0.78
Bloodstream infection 5 (11.4) 3 (12.5) 3 (20.0) 2 (15.4) 0.86
Empiric antimicrobial treatment 0.99
Unknown if adequate due to negative cultures 23 (52.3) 12 (50.0) 7 (46.7) 7 (53.8)
Adequate 17 (38.6) 10 (41.7) 6 (40.0) 5 (38.5)
Unknown if adequate due to diagnosis by antigenuria 3 (6.8) 2 (8.3) 2 (13.3) 1 (7.7)
Inadequate 1 (2.3) 0 0 0
b-lactamic more aminoglycoside 10 (22.7) 5 (20.8) 3 (20.0) 2 (15.4) 0.95
b-lactamic more quinolone 25 (56.8) 14 (58.3) 6 (40.0) 7 (53.8) 0.68
Mean blood pressure (mmHg) 68 (63 to 71) 66 (63 to 71) 69 (63 to 75) 69 (63 to 72) 0.63
Septic shock 38 (86.4) 21 (87.5) 13 (86.7) 11 (84.6) 0.99
Norepinephrine 38 (86.4) 21 (87.5) 13 (86.7) 11 (84.6) 0.99
Norepinephrine dose (μg/kg/minute) 0.5 (0.3 to 0.8) 0.5 (0.3 to 0.7) 0.5 (0.4 to 0.9) 0.5 (0.3 to 1.0) 0.77
Dobutamine 3 (6.8) 2 (8.3) 1 (6.7) 1 (7.7) 0.99
Dobutamine dose (μg/kg/minute) 6.0 (5.0 to 8.0) 6.0 (5.0 to 7.0) 5.0 8.0 0.56
PaO2/FIO2 ratio 199 (107 to 280) 152 (80 to 250) 138 (84 to 197) 128 (99 to 335) 0.38
Creatinine (mg/dl) 1.20 (0.80 to 2.06) 1.75 (1.00 to 2.17) 2.05 (1.10 to 3.07) 0.75 (0.47 to 1.42) 0.20
Bilirubin (mg/dl) 1.20 (0.64 to 2.30) 1.37 (0.88 to 2.56) 0.92 (0.48 to 1.44) 0.40 (0.17 to 0.66) 0.10
Leukocytes (×103/mm3) 12.2 (5.4 to 19.9) 10.2 (5.2 to 20.4) 16.4 (8.5 to 25.9) 13.8 (11.6 to 16.9) 0.81
Lactic acid (mmol/l) 2.35 (1.42 to 4.45) 3.20 (1.30 to 5.87) 3.80 (1.70 to 4.65) 1.30 (0.87 to 2.00) 0.048
Platelets (×103/mm3) 166 (86 to 224) 185 (78 to 312) 120 (43 to 193) 207 (103 to 294) 0.30
INR 1.42 (1.11 to 1.65) 1.38 (1.20 to 1.65) 1.24 (1.15 to 1.67) 1.21 (1.07 to 1.52) 0.63
aPTT (seconds) 33 (29 to 45) 35 (31 to 41) 36 (26 to 49) 30 (28 to 34) 0.40
APACHE II score 20 (16 to 25) 20 (14 to 24) 21 (18 to 23) 23 (14 to 29) 0.86
SOFA score 9 (7 to 12) 10 (9 to 14) 9 (8 to 12) 9 (6 to 11) 0.26
Survivors at 180 days 23 (52.3) 13 (54.2) 11 (73.3) 7 (53.8) 0.54
Survivors at 30 days 26 (59.1) 17 (70.8) 13 (86.7) 7 (53.8) 0.18
Data presented as number (percentage) or median (interquartile range). COPD, chronic obstructive pulmonary disease; PaO2/FIO2, pressure of arterial oxygen/
fraction inspired oxygen; aPTT, activated partial thromboplastin time; INR, International Normalized Ratio; APACHE, Acute Physiology and Chronic Health
Evaluation; SOFA, Sepsis-related Organ Failure Assessment.
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replication and transcription. M.11251A > G is a
synonymous polymorphism. Only m.4216T > C and
m.15452C > A provoke amino acid substitutions. The
first mutation produces the substitution of tyrosine by
histidine in position 304 of ND1 (p.MT-ND1:Y304H),
and the second produces a change of leucine by iso-
leucine in position 236 of cytochrome b (p.MT-CYB:
L236I). Supporting our results, the m.4216T allele has
been found to be a risk factor for mortality after
severe trauma [25]. However, there are no genetic dif-
ferences between the JT and other haplogroups in
respiratory complex IV mtDNA-encoded genes. The
question then arises of how can we explain the higher
respiratory complex IV levels in platelets of JT indivi-
duals with sepsis? Two hypotheses can therefore be
advanced.
First, it is now thought that respiratory complexes
interact within entities named supercomplexes [26] and
it has been shown that the assembly kinetic of respira-
tory complex IV or supercomplexes is faster in hap-
logroup J cybrids [27]. Therefore, the first hypothesis is
that the previously mentioned polymorphisms in
respiratory complex I (p.MT-ND1) and complex III (p.
MT-CYB) subunits may exert a protective effect on the
stability of respiratory chain complex IV.
Second, the expression of mtDNA genes is propor-
tional to the mtDNA copy number [28] and it has
recently been shown that mtDNA depletion occurs in
patients with sepsis and correlates with disease severity
[29]. When compared with cybrids from haplogroup H,
those from haplogroup J showed a significant increase
in mtDNA copy number. This increase was apparently
due to the presence of a mutation (m.295C > T) in a
control region important for mtDNA replication [30].
Therefore, the second hypothesis is that higher mtDNA
levels in JT haplogroup individuals could determine
higher levels of respiratory complex IV.
In addition to the three genes for respiratory complex
IV (MT-CO1 to MT-CO3), mtDNA also includes seven
genes (MT-ND1 to MT-ND-6 and MT-ND4L), one gene
(MT-CYB) and two genes (MT-ATP6 and MT-ATP8)
for oxidative phosphorylation (OXPHOS) complexes I,
III and V, respectively, and the RNAs (22 transfer RNAs
and two ribosomal RNAs) required for the expression of
those polypeptides. Interestingly, other studies have
shown that OXPHOS complex I [31] and OXPHOS
complex V [32] are affected in sepsis patients. OXPHOS
function has also been found affected in different tissues
from different organisms suffering from sepsis [4]. All of
these observations suggest a general effect of sepsis on
OXPHOS function. Moreover, it has been found that
the human blood leukocyte response to acute systemic
inflammation includes the modulation of translational
machinery and a transient dysregulation of leukocyte
bioenergetics. Significant decreases in mRNA abundance
were thus observed in the mitochondrial OXPHOS
complex I to complex V genes in humans [33], and
mtDNA is damaged in murine sepsis models [34-36].
Small OXPHOS differences due to haplogroup-defining
mtDNA population polymorphisms can thus determine
whether an individual will cross a pathological OXPHOS
threshold. Those individuals with a slightly higher
OXPHOS function will have a better chance of survival.
Particular mtDNA polymorphisms, modifying OXPHOS
capacities, therefore appear to contribute to sepsis survi-
val but they are only one of a combination of required
factors.
Some limitations of our study must be recognized.
First, the causal chain in the theoretical model is a fol-
lows: patients with the JT mtDNA haplogroup show
increase of COXq normalized by CS; and, finally, COXq
normalized by CS is associated with mortality. In our
study, only 15 patients have JT mtDNA; thus, the lack
of power is a drawback to test a complete model that
jointly includes mtDNA, COX specific activity, COX
quantity and survival. However, we found an association
between mtDNA haplogroups and survival controlling
for confounding variables, such as age and lactic acid
levels. The concordance between these findings and bio-
chemical data suggest that this genetic association is
real. Second, as previously discussed [4], the platelet
COX quantity is unlikely to be the factor that deter-
mines death in severe sepsis patients, although it prob-
ably mirrors the quantity in other tissue and organs -
but, because we did not want to use a very invasive pro-
tocol, we were not able to correlate this parameter
between different organs.
Conclusion
The novel findings of our study are that 1-month sur-
viving septic patients showed higher COXq/CSa than
Table 3 Comparison of COXa/CSa and COXq/CSa ratios
between JT and other mitochondrial DNA haplogroups
Other haplogroups JT haplogroup P value
Time of diagnosis (n = 81) (n = 15)
COXa/CSa ratio 2.84 (2.37 to 3.16) 3.25 (2.63 to 3.56) 0.04
COXq/CSa ratio 1.80 (1.25 to 2.90) 2.72 (1.57 to 3.38) 0.01
Day 4 (n = 62) (n = 10)
COXa/CSa ratio 2.81 (2.43 to 3.19) 3.24 (3.04 to 3.33) 0.01
COXq/CSa ratio 1.67 (1.27 to 3.14) 3.10 (2.52 to 3.45) 0.004*
Day 8 (n = 55) (n = 10)
COXa/CSa ratio 2.72 (2.32 to 3.26) 3.07 (2.83 to 3.15) 0.04
COXq/CSa ratio 1.67 (1.22 to 3.06) 3.39 (2.61 to 3.52) 0.002*
Data presented as median (interquartile range). COXa/CSa, cytochrome c
oxidase specific activity/citrate synthase specific activity; COXq/CSa,
cytochrome c oxidase quantity/citrate synthase specific activity. *Statistically
significant after Bonferroni correction.
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Table 4 Patients’ demographic and clinical characteristics according to mitochondrial DNA haplogroup
Other haplogroups (n = 81) JT haplogroup (n = 15) P value
Gender male 52 (64.2) 8 (53.3) 0.56
Age (years) 59 (48 to 68) 64 (54 to 81) 0.11
Diabetes mellitus 32 (39.5) 4 (26.7) 0.40
COPD 9(11.1) 1 (6.7) 0.99
Ischemic heart disease 6 (7.4) 1 (6.7) 0.99
Ischemic stroke 3 (3.7) 0 0.99
Site of infection 0.96
Respiratory 54 (66.7) 8 (53.3)
Abdominal 16 (19.8) 5 (33.3)
Urinary 3 (3.7) 1 (6.7)
Skin 5 (6.2) 1 (6.7)
Endocarditis 2 (2.5) 0
Others 1 (1.2) 0
Microorganism responsible
Unknown 43 (53.1) 6 (40.0) 0.41
Gram-positive 19 (23.5) 5 (33.3) 0.52
Gram-negative 18 (22.2) 4 (26.7) 0.74
Fungi 4 (4.9) 0 0.99
Anaerobe 1 (1.2) 0 0.99
Bloodstream infection 10 (12.3) 3 (20.0) 0.42
Empiric antimicrobial treatment 0.81
Unknown if adequate due to negative cultures 42 (51.9) 7 (46.7)
Adequate 32 (39.5) 6 (40.0)
Unknown if adequate due to diagnosis by antigenuria 6 (7.4) 2 (13.3)
Inadequate 1 (1.2) 0
b-lactamic more aminoglycoside 17 (21.0) 3 (20.0) 0.30
b-lactamic more quinolone 46 (56.8) 6 (40.0) 0.58
Mean blood pressure (mmHg) 68 (63 to 71) 69 (63 to 75) 0.74
Septic shock 70 (86.4) 13 (86.7) 0.99
Norepinephrine 70 (86.4) 13 (86.7) 0.99
Norepinephrine dose (μg/kg/minute) 0.5 (0.3 to 0.8) 0.5 (0.4 to 0.9) 0.75
Dobutamine 6 (7.4) 1 (6.7) 0.99
Dobutamine dose (μg/kg/minute) 6.0 (5.0 to 8.0) 5.0 0.57
PaO2/FIO2 ratio 160 (102 to 265) 138 (84 to 197) 0.98
Creatinine (mg/dl) 1.20 (0.70 to 2.00) 2.05 (1.10 to 3.07) 0.35
Bilirubin (mg/dl) 1.00 (0.55 to 2.30) 0.92 (0.48 to 1.44) 0.54
Leukocytes (×103/mm3) 12.2 (5.4 to 19.9) 16.4 (8.5 to 25.9) 0.82
Lactic acid (mmol/l) 2.20 (1.30 to 4.37) 3.80 (1.70 to 4.65) 0.20
Platelets (×103/mm3) 180 (89 to 266) 120 (43 to 193) 0.28
INR 1.32 (1.11 to 1.56) 1.24 (1.15 to 1.67) 0.35
aPTT (seconds) 33 (29 to 42) 36 (26 to 49) 0.30
APACHE II score 20 (16 to 25) 21 (18 to 23) 0.98
SOFA score 9 (7 to 12) 9 (8 to 12) 0.78
Survivors at 180 days 43 (53.1) 11 (73.3) 0.17
Survivors at 30 days 50 (61.7) 13 (86.7) 0.08
Data presented as number (percentage) or median (interquartile range). COPD, chronic obstructive pulmonary disease; PaO2/FIO2, pressure of arterial oxygen/
fraction inspired oxygen; aPTT, activated partial thromboplastin time; INR, International Normalized Ratio; APACHE, Acute Physiology and Chronic Health
Evaluation; SOFA, Sepsis-related Organ Failure Assessment.
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Table 5 Multiple logistic regression analyses to predict mortality
Odds ratio 95% confidence interval P value
First model: mortality at 1 month as dependent variable
Mitochondrial DNA haplogroup JT 0.18 0.04 to 0.94 0.04
Lactic acid 1.23 1.05 to 1.44 0.01
Age 1.03 0.99 to 1.06 0. 11
Second model: mortality at 6 months as dependent variable
Mitochondrial DNA haplogroup JT 0.27 0.07 to 1.03 0.056
Lactic acid 1.29 1.07 to 1.56 0.008
Age 1.03 1.001 to 1.071 0. 04
Third model: mortality at 1 month as dependent variable
COXq/CSa 0.53 0.30 to 0.93 0.03
Lactic acid 1.17 0.99 to 1.37 0.07
Age 1.03 0.99 to 1.07 0.12
Fourth model: mortality at 6 months as dependent variable
COXq/CSa 0.56 0.34 to 0.93 0.03
Lactic acid 1.18 0.98 to 1.42 0.08
Age 1.03 1.00 to 1.07 0.052
COXa/CSa, cytochrome c oxidase specific activity/citrate synthase specific activity; COXq/CSa, cytochrome c oxidase quantity/citrate synthase specific activity.
Figure 2 Association of survival with the JT mitochondrial DNA haplogroup. Cumulative proportion of surviving patients at 6 months
according to the JT mitochondrial DNA (mtDNA) haplogroup versus non-JT mtDNA haplogroup.
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nonsurviving individuals, that patients from the JT
mtDNA haplogroup showed a higher COXq/CSa ratio
and that JT patients had a higher 1-month survival than
patients from other mtDNA haplogroups.
Key messages
• One-month-surviving septic patients have a higher
platelet COXq/CSa ratio than nonsurvival patients.
• Septic patients with the JT mtDNA haplogroup
showed a higher platelet COXq/CSa ratio than those
from other mtDNA haplogroups.
• Septic patients with the JT mtDNA haplogroup
have higher survival at 1 month than those from
other mtDNA haplogroups.
Abbreviations
COX: cytochrome c oxidase; COXa/CSa: cytochrome c oxidase specific
activity/citrate synthase specific activity; COXq/CSa: cytochrome c oxidase
quantity/citrate synthase specific activity; CS: citrate synthase; mtDNA:
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